Autologous blood donation is an important alternative to homologous transfusion in scheduled surgery and is currently proposed for patients with clinically localized prostate cancer undergoing radical prostatectomy. Autologous blood donation has the bene®t of avoiding exposure to infectious and immunological complications. This strategy has been regarded as the standard of care for radical prostatectomy, but recent studies have demonstrated that it is not cost-effective and is of uncertain bene®t.
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1 Recent publications have shown that circulating prostate cells (CPCs) can be detected in blood specimens of patients with localized prostate cancer.
2 Malignant cells which may induce distant metastasis could exist among these CPCs. We investigated the presence of prostatic cells in autologous blood units (ABU) collected before transfusion and in peripheral blood pre-, per-(5 min after prostate removal) and postoperatively (3 days after surgery).
Method
Seventeen consecutive patients with clinically localized prostate cancer undergoing radical prostatecomy were enrolled into the study. ABUs (450 ml) were collected 3, 2 and 1 week before radical prostatectomy and stored in a SAG-M protective medium at 4 C. In the minutes preceding autotransfusion, 20 ml of each autologous blood specimen was collected and then pooled together for retrospective prostate-associated antigens (PAA) RT-PCR-based CPC detection.
Results
Of the 17 ABU extracts, PAA mRNAs were found in two patients (11%) (see Table 1 ), who were also listed in the six pre-operative positive patients. Peroperatively, 10 patients underwent prostate cell seeding, whereas 3 days later seven patients were still positive for CPC. Among the seven positive patients for CPC at day 3, only one had CPC in his ABU. One month later, a biological recurrence (PSAus b 0.3 ng/ml) was observed in three patients. The ®rst patient with positive ABU had a slight increase in PSAus (0.3 ng/ml), whereas a dramatic increase in serum PSAus was observed (PSAus 40 ng/ml) for the second one.
Conclusion
As suggested by a report showing the development of a donor-derived metastatic prostate cancer in a recipient following orthotopic heart transplantation, 3 prostate cell seeding may have a potential metastatic role. Therefore, like cell seeding induced by prostate mobilization, 4 ABD may be a source of prostate cell spread, further increasing the risk of metastatic process after radical prostatectomy. To withdraw CPC from ABU, treatment by ®ltration or, more safely, by irradiation 5 should be strongly recommended. In cases of early recurrence of the tumoural process after radical surgery, surgeons should bear in mind the potential side-effect of autologous blood transfusion. 
